Join
Live feed
·
PRReleasevia Quantisnow
Revolution Medicines Inc. logo

Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor

ByQuantisnow·Wall Street's wire, on your screen.
RVMD· Revolution Medicines Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVMD (Revolution Medicines Inc.) and more on Quantisnow.